Drospirenone, combination with

Other oral (drospirenone and norgestimate) and transdermal (levonorgestrel) progestagens also are available in combination with an estrogen. 

Cilest contains ethinylestradiol and norgestimate whereas Yasmin contains ethinylestradiol in combination with drospirenone. Both are combined oral contraceptives available as tablets, which have to be taken once daily for 21 days. Both are contraindicated in patients with venous thromboembolic diseases. 

In November 2000, drospirenone in combination with ethinylestradiol was introduced by Schering AG to the drug market in Germany as a contraceptive pill under the tradename Yasmin . Today, it is available almost worldwide, and is considered to be the most successful oral contraceptive of the past decade. 

With this combination of activities in one and the same dosage, drospirenone currently holds a leading position in hormonal contraception, although it requires a higher dosage than gestagens with an ethyl group at C(13). 

In the year 2000, Sobering introduced the contraceptive Yasmin , which contains 3 milligrams of drospirenone and 30 micrograms of ethynyloestradiol. In 2004 followed Angeliq , a combination product as hormone replacement for women during menopause, and for prevention of post-menopausal osteoporosis, with 0,5 milligrams of drospirenone and 1 milligram of oestradiol. 

Rosa MI, Madeira K, Medeiros LR. Can a meta-analysis that included articles with high heterogeneity appropriately evaluate the risk of venous thromboembolism in users of combined hormonal contraceptives containing drospirenone or desogestrel Eur J Contracept Reprod Health Care 2013 18(2) 137-9. 

---